Business Wire

THALES

23.5.2024 09:01:29 CEST | Business Wire | Press release

Share
Thales Leads Innovative Digital Transformation of the Mauritius National Identity System

The Mauritius Prime Minister's Office (PMO) has entrusted the consortium led by Thales, which includes the leading Mauritian-grown IT provider Harel Mallac Technologies (HMT), with a crucial step toward developing a comprehensive National ID system to improve citizen services and bolstering identity security. This partnership sets the foundations for the next generation digital journey of Mauritius, fully aligned with the country’s 2030 digital strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240523106005/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

©Thales

This ambitious modernisation effort draws on Thales experience from 300 government projects worldwide, and ensures that field-proven technology can be associated for timely delivery and reliable project execution. It is a long-term partnership providing consistent and expert support in all key components of the identity scheme, from citizen enrolment to physical and digital ID issuance. This end-to-end approach effectively meets future evolutions as well as potential identity threats.

As part of the 10-year contract Thales is providing a powerful and modular Identity Management System to securely issue cutting-edge eID cards and its mobile companion, the Digital ID Wallet. The solution assures comprehensive trust and privacy in daily interactions between public entities and individuals. The user experience is at the core of this modernisation drive, illustrated by the wider range of new functionalities and services it brings to citizens.

The citizen’s journey starts with a frictionless enrolment process, which can be initiated online from the comfort of home to save citizens time when visiting the enrolment centre. Once enrolled, the holder will receive a new eID card which relies on the latest Thales embedded software and advanced security features, including high resolution colour photo1, to effectively combat forgery and identity theft. For more convenience, self-service kiosks will be installed at dedicated spots to enable users to update their ID cards’ information (with new address, etc) and manage the PIN code associated with the digital certificates stored in their card.

Citizens can also activate their Digital ID Wallet, a secure mobile application where they can securely store and share digital identity documents. The wallet will initially include digital versions of the identity card and will subsequently contain other official documents such as birth and marriage certificates. These may then be shared both online and in-person. Citizens will also be able to digitally sign documents with a one-time certificate as well as log in to online government services by using their digital wallet. For service providers (public administrations, banks, retailers, universities, etc…) it will be a simpler and more secure way to verify identities. Citizens’ control over their personal data is guaranteed thanks to stringent data privacy and consent management mechanisms.

Mauritius identity cards production will benefit from Thales factories’ sustainability action plan, which aims to reduce the carbon footprint by utilising 100% renewable electricity, optimising energy consumption and minimising waste. As a complement to this approach, the Mauritius project is part of Thales' offsetting program which supports sustainable initiatives2 worldwide (selected in collaboration with Climate Impact Partner) by offsetting the carbon emissions from all its travel and ID solutions.

During the official launching on 26th February 2024 of the national ID card at the Sir Harilal Vaghjee Memorial Hall, Government Centre, Port Louis, it was stated that:
“The purpose of modernising the present system with sophisticated and next generation technology is to enable new services while increasing citizen security and convenience. The next-generation ID system will lay the foundation for supporting the country's digital transformation, benefiting all stakeholders and fostering economic growth.”

“With this implementation, blending ID cards and digital identity, Mauritius fully leverages the best of both worlds, offering the optimal combination of security and ease,” says Youzec Kurp, VP Identity and Biometrics Solutions at Thales. “The new Mauritius ID system stands as one of the most advanced and marks the first implementation of a fully interoperable Digital ID Wallet in Africa, adhering to international ISO standards. This positions Mauritius amongst the pioneer countries in identity solutions worldwide.”

1 The new e-document incorporates latest generation of embedded software together with advanced physical features such as Thales Colour Laser Shield technology (high resolution colour portrait) ensuring state-of-the-art protection against counterfeiting for both blank and personalised documents, True Vision (high resolution true-colour UV picture), transparent window element with the holders’ ghost image, and Secure Surface 3D tactile features combining movement and light reflection.
2 Example of supported projects in 2023: Vichada Afforestation in Colombia, Aqua Clara Water Filters in Kenya, Renewable Energy Portfolio worldwide.

About Thales

Thales (Euronext Paris: HO) is a global leader in advanced technologies specialized in three business domains: Defence & Security, Aeronautics & Space, and Cybersecurity & Digital identity.

It develops products and solutions that help make the world safer, greener and more inclusive.

The Group invests close to €4 billion a year in Research & Development, particularly in key innovation areas such as AI, cybersecurity, quantum technologies, cloud technologies and 6G.

Thales has close to 81,000* employees in 68 countries. In 2023, the Group generated sales of €18.4 billion.

* These figures exclude the ground transportation business, which is being divested.

PLEASE VISIT

Thales Group
Digital Identity & Security

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240523106005/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye